Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)

Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir/pibrentasvir (GLE/PIB) treatment and its impact on patient-reported outcomes (PROs) in underserved populations who are not typically included in cl...

Full description

Bibliographic Details
Main Authors: Markus Cornberg, Albrecht Stoehr, Uwe Naumann, Gerlinde Teuber, Hartwig Klinker, Thomas Lutz, Hjördis Möller, Dennis Hidde, Kristina Lohmann, Karl-Georg Simon
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Viruses
Subjects:
direct-acting antiviral
glecaprevir/pibrentasvir
hepatitis C virus
real world evidence
German Hepatitis C-Registry
Online Access:https://www.mdpi.com/1999-4915/14/7/1541

Internet

https://www.mdpi.com/1999-4915/14/7/1541

Similar Items